Skip to main content
. 2023 Feb 23;9(1):e002789. doi: 10.1136/rmdopen-2022-002789

Figure 2.

Figure 2

Proportions of patients achieving MDA components at weeks 24 (A; reading session 1), 52 (B; reading session 2) and 100 (C; reading session 3) summarised by radiographic progression status at the same time points, with progression defined as change from baseline in total PsA-modified vdH-S score >0.5. Progressors (P)—week 24: Q4W, N=50; Q8W, N=62; week 52: Q4W, N=64; Q8W, N=77; week 100: Q4W, N=57, Q8W, N=77. Non-progressors (NP)—week 24: Q4W, N=190; Q8W, N=181; week 52: Q4W, N=162; Q8W, N=157; week 100: Q4W, N=153, Q8W, N=138. GUS, guselkumab; HAQ-DI, Health Assessment Questionnaire-Disability Index; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PsA-modified vdH-S score, van der Heijde-Sharp score modified for psoriatic arthritis; PtGA, patient global assessment; Q4W, every 4 weeks; Q8W, every 8 weeks; SJC, swollen joint count; TJC, tender joint count.